Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
RLMD
SellSinkerRelmada Therapeutics, Inc. · Healthcare · United States · $462M · Avg Vol: $5M/d
COMPANY DESCRIPTION
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing innovative treatments for central nervous system (CNS) disorders, primarily focusing on major depressive disorder (MDD) and neuropathic pain. The company's lead investigational compound, REL-1017, is a novel NMDA receptor modulator with the potential to offer a new approach for treating depression. Relmada operates as a niche biotech player with its pipeline concentrated on high-unmet-need CNS conditions.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -1.52 | -0.94 | -0.76 | -1.45 | — | -0.91 | -0.48 | -0.56 | — |
| Shares | 105.0M | 105.0M | 105.0M | 73.3M | -30.2% | — | — | — | — |
| Debt | — | — | — | — | — | — | — | — | — |
| Equity | 140.4M | 85.4M | 35.5M | 86.5M | -14.9% | — | — | — | — |
| Op CF | -103.8M | -51.7M | -51.8M | -45.8M | — | -12.1M | — | — | — |
| Inv CF | 19.7M | 50.5M | 51.6M | -48.1M | — | — | — | — | — |
| Fin CF | 45.0M | -98.5K | -40.3K | 93.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of RLMD are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| RLMD | Relmada Therapeutics, Inc.(you) | $462M | 20 | Sell |
| DNA | Ginkgo Bioworks Holdings, Inc. | $469M | 20 | Sell |
| RZLT | Rezolute, Inc. | $445M | 21 | Sell |
| BNTC | Benitec Biopharma Inc. | $428M | 23 | Sell |
| AVIR | Atea Pharmaceuticals, Inc. | $430M | 17 | Strong Sell |
| ARCT | Arcturus Therapeutics Holdings Inc. | $432M | 25 | Sell |
| MPLT | MapLight Therapeutics, Inc. | $584M | 21 | Sell |
| PRLD | Prelude Therapeutics Incorporated | $437M | 25 | Sell |
| LRMR | Larimar Therapeutics, Inc. | $417M | 16 | Strong Sell |
| EDIT | Editas Medicine, Inc. | $485M | 14 | Strong Sell |
Peer medians: ROE -30.7% · P/E 27.0x · Gross margin 58.3%